Canton Strategic Holdings, Inc.
NCM: CNTNLive Quote
About Canton Strategic Holdings, Inc.
Healthcare
Biotechnology
Canton Strategic Holdings, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. The company also involved in research and development of GV104, a buccal film technology, which has completed Phase 1 trial for respiratory and/or nervous system depression in military personnel and chemical incident responders; and GV023, an oral formulation of infliximab, addresses a critical limitation of the IV gold standard by eliminating the treatment burden of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was founded in 2017 and is based in Red Bank, New Jersey.
📊 Fundamental Analysis
Canton Strategic Holdings, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -18.0%, which indicates that capital utilization is currently under pressure.
At a current price of $2.98, CNTN currently sits at the 24th percentile of its 52-week range (Range: $1.05 - $9.08).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$187.08M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
1.60
52W High
$9.08
52W Low
$1.05
Avg Volume
896K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App